Are we measuring progress in AI-driven drug discovery the right way? Rafael Rosengarten explores this question with Andrii Buvailo, co-founder of BioPharmaTrend and one of the industry’s most perceptive analysts of AI in biotech and pharma.
They trace the evolution of AI-driven drug discovery, examine why counting AI-discovered drugs gives an incomplete picture of progress, and explore where AI can create value today. Andrii also considers why the technology has become so polarizing, what remains distinctly human in an AI-enabled world, and how patient data and more representative biological systems could reshape drug development.
Podden och tillhörande omslagsbild på den här sidan tillhör
Genialis. Innehållet i podden är skapat av Genialis och inte av,
eller tillsammans med, Poddtoppen.
